Abstract:Development of anticancer drugs targeting Aurora B, an important member of the serine/threonine kinases family, has been extensively focused on in recent years. In this work, by applying an integrated computational method, including comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), homology modeling and molecular docking, we investigated the structural determinants of Aurora B inhibitors based on three different series of derivatives of 108 molecules. The resultant optimum 3D-QSAR models exhibited (q(2) = 0.605, r(2) (pred) = 0.826), (q(2) = 0.52, r(2) (pred) = 0.798) and (q(2) = 0.582, r(2) (pred) = 0.971) for MK-0457, GSK1070916 and SNS-314 classes, respectively, and the 3D contour maps generated from these models were analyzed individually. The contour map analysis for the MK-0457 model revealed the relative importance of steric and electrostatic effects for Aurora B inhibition, whereas, the electronegative groups with hydrogen bond donating capacity showed a great impact on the inhibitory activity for the derivatives of GSK1070916. Additionally, the predictive model of the SNS-314 class revealed the great importance of hydrophobic favorable contour, since hydrophobic favorable substituents added to this region bind to a deep and narrow hydrophobic pocket composed of residues that are hydrophobic in nature and thus enhanced the inhibitory activity. Moreover, based on the docking study, a further comparison of the binding modes was accomplished to identify a set of critical residues that play a key role in stabilizing the drug-target interactions. Overall, the high level of consistency between the 3D contour maps and the topographical features of binding sites led to our identification of several key structural requirements for more potency inhibitors. Taken together, the results will serve as a basis for future drug development of inhibitors against Aurora B kinase for various tumors.

In Vitro and in Vivo Characterization of a Benzofuran Derivative, a Potential Anticancer Agent, As a Novel Aurora B Kinase Inhibitor.

Design, Synthesis, Biological Evaluation of 6-(2-amino-1h-benzo[d]imidazole-6-yl)quinazolin-4(3h)-one Derivatives As Novel Anticancer Agents with Aurora Kinase Inhibition.

Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model

A New Small-Molecule Aurora B Inhibitor Shows Antitumor Activity in Human Cancer Cell Lines

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Structure-based Drug Design: Synthesis and Biological Evaluation of Quinazolin-4-amine Derivatives As Selective Aurora A Kinase Inhibitors.

A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.

Discovery of new pyrazole-4-carboxamide analogues as potential anticancer agents targeting dual Aurora kinase A and B

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

3D-QSAR and Molecular Docking Studies on Derivatives of MK-0457, GSK1070916 and SNS-314 As Inhibitors Against Aurora B Kinase.

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.

Design, Synthesis and Bioevaluation of Dihydropyrazolo[3,4-B]pyridine and Benzo[4,5]imidazo[1,2-A]pyrimidine Compounds As Dual KSP and Aurora-A Kinase Inhibitors for Anti-Cancer Agents.

Discovery of Novel 2,4-Disubstituted Pyrimidines As Aurora Kinase Inhibitors.

Synthesis and antitumor activities of novel 3-(6-aminopyridin-3-yl)benzamide derivatives: Inducing cell cycle arrest and apoptosis via AURKB transcription inhibition

Identification of an Aurora Kinase Inhibitor Specific for the Aurora B Isoform

Synthesis and Biological Evaluation of 2,4-Diaminopyrimidines As Selective Aurora A Kinase Inhibitors.

Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen

In Vitro and in Vivo Antineoplastic Activity of A Novel Bromopyrrole and Its Potential Mechanism of Action

Discovery of Inhibitors of Aurora/PLK Targets As Anticancer Agents.

The Synthesis and Anti-Tumour Properties of Novel 4-Substituted Phthalazinones As Aurora B Kinase Inhibitors.